Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | NEK2 | P51955 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15381287 | 0.81 | CHRM2 (0.34) | CHRM2CHRM3NEK2ALDH1A1 | |
| SCHEMBL15478455 | 0.78 | ALDH1A1 (0.33) | ALDH1A1MAPK1ATM | |
| SCHEMBL15434338 | 0.78 | ALDH1A1 (0.35) | CHRM2CHRM3NEK2ALDH1A1MAPK1 | |
| SCHEMBL4868611 | 0.73 | PIN1 (0.34) | CHRM2CHRM3NEK2ALDH1A1MAPK1 | |
| SCHEMBL4872745 | 0.71 | PIN1 (0.48) | ALDH1A1MAPK1ATM | |
| SCHEMBL4903606 | 0.70 | CHRM2 (0.34) | CHRM2CHRM3ALDH1A1MAPK1ATM | |
| SCHEMBL2604290 | 0.67 | — | — | |
| SCHEMBL7402227 | 0.65 | NEK2 (0.33) | CHRM2CHRM3NEK2 | |
| SCHEMBL24753711 | 0.64 | CHRM2 (0.36) | CHRM2CHRM3NEK2 | |
| SCHEMBL15381442 | 0.64 | NEK2 (0.35) | CHRM2CHRM3NEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3791875-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | Pain Therapeutics, Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3054956-B1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS INC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-2882428-B1 | A METHOD OF INHIBITING TAU PHOSPHORYLATION | PAIN THERAPEUTICS INC (US) | 2019-01-16 | — | — | EP | disclosed |
| EP-2872899-B1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | PAIN THERAPEUTICS INC (US) | 2018-07-11 | — | — | EP | disclosed |
| US-9500640-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9433604-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9354223-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-9340558-B2 | Filamin a binding anti-inflammatory and analgesic | PAIN THERAPEUTICS INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| US-20140113895-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | PAIN THERAPEUTICS, INC. | 2014-04-24 | — | — | US | disclosed |
| US-8653068-B2 | Filamin A binding anti-inflammatory and analgesic | PAIN THERAPEUTICS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20140017699-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-8580809-B2 | Filamin A-binding anti-inflammatory analgesic | PAIN THERAPEUTICS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580808-B2 | Filamin A-binding anti-inflammatory analgesic | Pain Therapeutic, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH | 2008-12-11 | — | — | US | disclosed |
| US-7439251-B2 | Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor | ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH (IL) | 2008-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306103-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL AND PERIPHERAL NERVOUS SYSTEM DISORDERS AND NOVEL COMPOUNDS USEFUL THEREFOR | PMP22, PYGB, GAP43 | CHRM2 365/4885CHRM3 302/4885NEK2 967/4885 |
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | CHRM2 2961/4885CHRM3 3059/4885NEK2 620/4885 |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | FLNA, FLNB, FSCN1 | CHRM2 3080/4885CHRM3 3501/4885NEK2 502/4885 |
| US-20140113895-A1 | FILAMIN A BINDING ANTI-INFLAMMATORY AND ANALGESIC | FLNA, FLNB, OPRK1 | CHRM2 1449/4885CHRM3 1430/4885NEK2 883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.